NeuroPace, Inc. (NPCE)Healthcare | Medical Devices | Mountain View, United States | NasdaqGM
12.68 USD
-0.32
(-2.462%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:31 a.m. EDT
NeuroPace presents a classic value trap scenario where the balance sheet appears fortress-like due to low debt relative to assets, yet the business fundamentals are deteriorating rapidly. While the company boasts a massive current ratio and manageable absolute debt figures, the operational reality is stark: negative free cash flow, negative operating margins, and a return on equity that is deeply negative. The market has correctly priced this into a 38% decline over the last four years, despite a recent year-over-year price recovery. This recovery is likely a technical bounce rather than a fundamental turnaround, especially given the regulatory headwinds mentioned in recent news regarding FDA requests for more evidence. The short-term outlook remains bearish to neutral. The stock trades significantly below its 50-day and 200-day moving averages, indicating persistent selling pressure. With no dividend to provide income and a high beta amplifying downside risk, there is no margin of safety here. The 'fortress' balance sheet is insufficient to offset the risk of continued cash burn and regulatory uncertainty. Investors should avoid this security until there is concrete evidence of sustained profitability or a clear path to reducing the cash burn rate without diluting shareholders further. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.064674 |
| AutoETS | 0.069467 |
| AutoARIMA | 0.069467 |
| AutoTheta | 0.085143 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.81 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.263 |
| Excess Kurtosis | 0.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 588.496 |
| Revenue per Share | 3.185 |
| Market Cap | 435,231,776 |
| Forward P/E | -58.30 |
| Beta | 1.87 |
| Profit Margins | -17.86% |
| Website | https://www.neuropace.com |
As of Oct. 10, 2026, 2:31 a.m. EDT: Options activity is extremely thin and lacks directional conviction. Call volume is negligible across all expirations, with open interest concentrated in out-of-the-money strikes but representing minimal speculative positioning. Put activity is similarly sparse, appearing only in distant February 2027 contracts. The lack of significant flow or implied volatility spikes suggests speculators are largely absent or indifferent to near-term price moves.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.20147872 |
| Address1 | 455 North Bernardo Avenue |
| All Time High | 27.38 |
| All Time Low | 1.22 |
| Ask | 17.12 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 117,730 |
| Average Daily Volume3 Month | 167,428 |
| Average Volume | 167,428 |
| Average Volume10Days | 117,730 |
| Beta | 1.867 |
| Bid | 10.16 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 0.347 |
| City | Mountain View |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 12.68 |
| Current Ratio | 4.944 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 13.265 |
| Day Low | 12.68 |
| Debt To Equity | 588.496 |
| Display Name | NeuroPace |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,480,200 |
| Earnings Call Timestamp Start | 1,786,480,200 |
| Earnings Timestamp | 1,786,478,400 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | -11,877,000 |
| Ebitda Margins | -0.11101 |
| Enterprise To Ebitda | -38.18 |
| Enterprise To Revenue | 4.238 |
| Enterprise Value | 453,463,808 |
| Eps Current Year | -0.43369 |
| Eps Forward | -0.21749 |
| Eps Trailing Twelve Months | -0.57 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 14.1064 |
| Fifty Day Average Change | -1.4263992 |
| Fifty Day Average Change Percent | -0.10111717 |
| Fifty Two Week Change Percent | 20.147873 |
| Fifty Two Week High | 19.6 |
| Fifty Two Week High Change | -6.92 |
| Fifty Two Week High Change Percent | -0.35306123 |
| Fifty Two Week Low | 9.22 |
| Fifty Two Week Low Change | 3.46 |
| Fifty Two Week Low Change Percent | 0.37527114 |
| Fifty Two Week Range | 9.22 - 19.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,619,098,200,000 |
| Float Shares | 25,571,241 |
| Forward Eps | -0.21749 |
| Forward P E | -58.301533 |
| Free Cashflow | -2,629,250 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 220 |
| Fullday Change | -0.3199997 |
| Fullday Change Percent | -2.4615362 |
| Fullday Price | 12.68 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.77382004 |
| Gross Profits | 82,793,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.044650003 |
| Held Percent Institutions | 0.97332 |
| Implied Shares Outstanding | 34,324,274 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-04-22 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. |
| Long Name | NeuroPace, Inc. |
| Market | us_market |
| Market Cap | 435,231,776 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_125322 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -16,173,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 489,120,904 |
| Number Of Analyst Opinions | 10 |
| Open | 13.06 |
| Operating Cashflow | -11,241,000 |
| Operating Margins | -0.22531 |
| Overall Risk | 9 |
| Phone | 650 237 2700 |
| Previous Close | 13.0 |
| Price Eps Current Year | -29.237474 |
| Price Hint | 2 |
| Price To Book | 36.541786 |
| Price To Sales Trailing12 Months | 4.067853 |
| Profit Margins | -0.17864999 |
| Quick Ratio | 3.822 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.1 |
| Region | US |
| Regular Market Change | -0.32 |
| Regular Market Change Percent | -2.46154 |
| Regular Market Day High | 13.265 |
| Regular Market Day Low | 12.68 |
| Regular Market Day Range | 12.68 - 13.265 |
| Regular Market Open | 13.06 |
| Regular Market Previous Close | 13.0 |
| Regular Market Price | 12.68 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 66,779 |
| Return On Assets | -0.0747 |
| Return On Equity | -1.03273 |
| Revenue Growth | 0.171 |
| Revenue Per Share | 3.185 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 34,324,274 |
| Shares Percent Shares Out | 0.026300002 |
| Shares Short | 903,626 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 911,415 |
| Short Name | Neuropace, Inc. |
| Short Percent Of Float | 0.030299999 |
| Short Ratio | 6.86 |
| Source Interval | 15 |
| State | CA |
| Symbol | NPCE |
| Target High Price | 22.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 20.0 |
| Target Median Price | 20.0 |
| Total Cash | 51,699,000 |
| Total Cash Per Share | 1.506 |
| Total Debt | 69,931,000 |
| Total Revenue | 106,993,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.2138 |
| Two Hundred Day Average Change | -2.5338001 |
| Two Hundred Day Average Change Percent | -0.16654617 |
| Type Disp | Equity |
| Volume | 66,779 |
| Website | https://www.neuropace.com |
| Zip | 94,043 |